Anticoagulation after coronary stenting: a systemic review
@article{Dong2017AnticoagulationAC, title={Anticoagulation after coronary stenting: a systemic review}, author={Zhe Dong and Jingang Zheng}, journal={British Medical Bulletin}, year={2017}, volume={123}, pages={79–89} }
Introduction or background
Anticoagulant therapy is mainly used to prevent patients from suffering coronary and systemic thromboembolism after stenting. Many studies have been done to formulate an optimized regimen of a post-PCI or long-time anticoagulant therapy. Recent advances in the selection and duration of anticoagulant agents will be conducive to the management of patients who are considered to need anticoagulant therapy after stenting.
Sources of data
Key recent published literature…
5 Citations
Effects of ticagrelor and clopidogrel on serum homocysteine level and neutrophil-to-lymphocyte ratio in elderly patients with coronary heart disease
- Medicine
- 2020
Ticagrelor combined with aspirin is markedly effective in the treatment of patients undergoing PCI, which can decrease Hcy and NLR, improve left ventricular function and reduce the incidence of adverse events.
Biological Responses in the Blood and Organs of Rats to Intraperitoneal Inoculation of Graphene and Graphene Oxide
- MedicineMaterials
- 2022
This study contributes to further clarifying the possible toxicity of graphene and its potential biomedical applications by assessing potential changes in the blood and organs after 15 and 30 days of inoculation with graphene.
Biological Activities and Phytochemicals of Lungworts (Genus Pulmonaria) Focusing on Pulmonaria officinalis
- BiologyApplied Sciences
- 2022
An attempt has been made in this study to compile the phytochemicals and biological properties of lungworts to not only provide the resources for the design of further research to develop the pharmacological application of Lungworts, but also to highlight the gaps and provide suggestions for future development.
Amphiphilic Core Cross-Linked Star Polymers for the Delivery of Hydrophilic Drugs from Hydrophobic Matrices.
- Materials Science, BiologyBiomacromolecules
- 2021
These results support the use of core cross-linked star polymer amphiphiles for the delivery of hydrophilic drugs from hydrophobic polymer matrices, developed for application as drug-eluting and biodegradable coronary artery stents.
References
SHOWING 1-10 OF 47 REFERENCES
Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation
- Medicine, BiologyPostepy w kardiologii interwencyjnej = Advances in interventional cardiology
- 2016
The present overview summarizes the recent advances in antithrombotic management used in atrial fibrillation patients undergoing PCI for stable coronary artery disease or acute coronary syndrome (ACS) and discusses the use of anticoagulation in addition to antiplatelet therapy for secondary prevention in patients with ACS.
Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies
- MedicineCardiovascular Drugs and Therapy
- 2016
It is shown that among patients undergoing coronary stent implantation, requiring chronic OAC, the use of a TT is associated with a significant reduction in overall mortality, recurrent MI and ischemic stroke, and benefits in mortality were lost in patients at high-risk for bleedings.
Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial.
- MedicineJournal of the American College of Cardiology
- 2015
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
- Medicine, BiologyEuropean heart journal
- 2013
In patients with a recent acute coronary syndrome, the addition of a new oral anticoagulant to antiplatelet therapy results in a modest reduction in cardiovascular events but a substantial increase in bleeding, most pronounced when new oral ants are combined with dual antiplatelets therapy.
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
- MedicineThe Lancet
- 2013
The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale.
- MedicineAmerican heart journal
- 2008
[Diagnosis and management of acute pulmonary embolism. ESC guidelines 2014].
- MedicineHerz
- 2015
In the 2014 guidelines of the European Society of Cardiology on the diagnosis and management of acute PE, several new recommendations have been issued based on new study data, and there is now good evidence for the use of age-adjusted D-dimer cut-off levels.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
- MedicineThe Lancet
- 2014
Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
- MedicineCardiovascular revascularization medicine : including molecular interventions
- 2017
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
- Medicine, BiologyThe American journal of cardiology
- 2004